Respiratory therapy

COVID-19 Long Haulers Get At-Home Relief for Breathing Difficulties, According to Diana Berrent, Founder of Survivor Corps

Tuesday, March 2, 2021 - 4:02pm

For asthma sufferers with known or suspected COVID-19, breathing difficulty can be particularly debilitating making finding treatments that can be conducted safely at home an additional concern.

Key Points: 
  • For asthma sufferers with known or suspected COVID-19, breathing difficulty can be particularly debilitating making finding treatments that can be conducted safely at home an additional concern.
  • Because the virus is novel, we began with almost no information whatsoever, and many survivors had to silently suffer through lingering symptoms of COVID-19.
  • COVID-19 patients report severe, painful, persistent symptoms like fatigue, muscle weakness, sleep difficulties, and headaches along with difficulty breathing.
  • When combatting COVID symptoms, a convenient option for migraines or breathing issues associated with asthma is gammaCore, a non-drug, at-home therapy.

Lisa Deschamps Joins Verona Pharma as Non-Executive Director

Tuesday, March 2, 2021 - 7:00am

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.

Key Points: 
  • Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.
  • The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (Ensifentrine as a Novel inHAled Nebulized COPD thErapy) for COPD maintenance treatment.
  • All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements.
  • These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Verona Pharma to Present at H.C. Wainwright Global Life Sciences Virtual Conference

Monday, March 1, 2021 - 7:00am

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.

Key Points: 
  • Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.
  • The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (Ensifentrine as a Novel inHAled Nebulized COPD thErapy) for COPD maintenance treatment.
  • All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements.
  • These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Tezepelumab Is the First Biologic to Consistently and Significantly Reduce Exacerbations in Broad Population of Severe Asthma Patients

Friday, February 26, 2021 - 2:00pm

AstraZeneca is an established leader in respiratory care, and its inhaled and biologic medicines reached more than 53 million patients in 2019.

Key Points: 
  • AstraZeneca is an established leader in respiratory care, and its inhaled and biologic medicines reached more than 53 million patients in 2019.
  • Efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma: results from the phase 3 NAVIGATOR study.
  • The management of severe asthma: economic analysis of the cost of treatments for severe asthma.
  • Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe, Uncontrolled Asthma (DESTINATION) [Online].

Mabry Health Care & Rehab Center Partners with Encore Healthcare to add Respiratory Therapy Services and Pulmonary Rehab Program

Thursday, February 25, 2021 - 1:41pm

GAINSBORO, Tenn., Feb. 25, 2021 /PRNewswire/ --Mabry Health Care & Rehab Center is excited to announce a clinical respiratory excellence partnership with Encore Healthcare, based in Livingston, TN.

Key Points: 
  • GAINSBORO, Tenn., Feb. 25, 2021 /PRNewswire/ --Mabry Health Care & Rehab Center is excited to announce a clinical respiratory excellence partnership with Encore Healthcare, based in Livingston, TN.
  • In addition to these changes, Mabry is expanding into another key service greatly needed in the Upper Cumberland area, Respiratory Therapy Services provided by Encore Healthcare.
  • Encore's Respiratory Therapy services will allow for the advanced care and management of patients with COPD and other chronic respiratory conditions including tracheostomized patients and those requiring specialty respiratory equipment.
  • Mabry Health Care & Rehab Center takes great pride in maintaining the highest standards, employing quality nurses and staff to better care for your loved one.

Verona Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

Thursday, February 25, 2021 - 7:00am

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.

Key Points: 
  • Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.
  • Two additional formulations of ensifentrine are currently in Phase 2 development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI).
  • Ensifentrine is being evaluated in a pilot clinical study in patients hospitalized with COVID-19 and has potential applications in cystic fibrosis, asthma and other respiratory diseases.
  • Verona Pharma has also implemented measures to help keep the Companys employees, families, and local communities healthy and safe.

$1.4 Billion Growth in Global Commercial Aircraft Oxygen System Market During 2021-2025 | Featuring Key Vendors Including Adams Rite Aerospace Inc., AMETEK Inc., and Cobham Plc | Technavio

Wednesday, February 24, 2021 - 3:15pm

NEW YORK, Feb. 24, 2021 /PRNewswire/ --Technavio announces the release of its latest report on the commercial aircraft oxygen system market.

Key Points: 
  • NEW YORK, Feb. 24, 2021 /PRNewswire/ --Technavio announces the release of its latest report on the commercial aircraft oxygen system market.
  • Commercial Aircraft Oxygen System Market: Key Findings
    Commercial aircraft oxygen system market value to grow by USD 1.4 billion during 2021-2025.
  • Commercial Aircraft Oxygen System Market: Growth Drivers
    Preference for aircraft with advanced technologies is one of the prime factors driving the growth of the market.
  • Technavio's SUBSCRIPTION platform
    Commercial Aircraft Oxygen System Market: Major Vendors
    Adams Rite Aerospace Inc. operates its business through the Unified segment.

Mechanical Ventilators Market Size Worth $3.9 Billion By 2028 | CAGR: 4.9%: Grand View Research, Inc.

Wednesday, February 24, 2021 - 9:05am

SAN FRANCISCO, Feb. 24, 2021 /PRNewswire/ -- The global mechanical ventilator market size is expected to reach USD 3.9 billion by 2028, according to a new report by Grand View Research Inc.

Key Points: 
  • SAN FRANCISCO, Feb. 24, 2021 /PRNewswire/ -- The global mechanical ventilator market size is expected to reach USD 3.9 billion by 2028, according to a new report by Grand View Research Inc.
  • Key suggestions from the report:
    Transport and portable ventilators are expected to witness a lucrative CAGR of over 5.2% over the forecast period.
  • Therefore, the rise in prevalence of such diseases, introduction and availability of portable, cost contained, and easy-to-use mechanical ventilators for the treatment of respiratory conditions is expected to drive the market.
  • Grand View Research has segmented the global mechanical ventilators market based on product and region:
    Mechanical Ventilators Product Outlook (Revenue, USD Million, 2016 - 2028)

Mechanical Ventilators Market Size Worth $3.9 Billion By 2028 | CAGR: 4.9%: Grand View Research, Inc.

Wednesday, February 24, 2021 - 9:05am

SAN FRANCISCO, Feb. 24, 2021 /PRNewswire/ -- The global mechanical ventilator market size is expected to reach USD 3.9 billion by 2028, according to a new report by Grand View Research Inc.

Key Points: 
  • SAN FRANCISCO, Feb. 24, 2021 /PRNewswire/ -- The global mechanical ventilator market size is expected to reach USD 3.9 billion by 2028, according to a new report by Grand View Research Inc.
  • Key suggestions from the report:
    Transport and portable ventilators are expected to witness a lucrative CAGR of over 5.2% over the forecast period.
  • Therefore, the rise in prevalence of such diseases, introduction and availability of portable, cost contained, and easy-to-use mechanical ventilators for the treatment of respiratory conditions is expected to drive the market.
  • Grand View Research has segmented the global mechanical ventilators market based on product and region:
    Mechanical Ventilators Product Outlook (Revenue, USD Million, 2016 - 2028)

Clinical Validation in Dark Pigmented Individuals Finds CIRCUL™ Pulse Oximetry Ring Provides Reliable Oxygen Saturation Readings Addressing Potential Discrimination in Traditional Pulse Oximeters

Tuesday, February 23, 2021 - 7:00pm

The CIRCUL Ring clinical validation study, conducted at the Tongde Hospital of Zhejiang Province, China, compared simultaneous measurements for the CIRCUL Ring and an arterial blood gas (ABG) test from 12 individuals (4 Black, ~33% of total enrollment).

Key Points: 
  • The CIRCUL Ring clinical validation study, conducted at the Tongde Hospital of Zhejiang Province, China, compared simultaneous measurements for the CIRCUL Ring and an arterial blood gas (ABG) test from 12 individuals (4 Black, ~33% of total enrollment).
  • For Black individuals, 100 oxygen saturation measurements from the CIRCUL Ring showed excellent correlation with data obtained simultaneously from ABG testing for oxygen saturations ranging from 100% to 70%.
  • The ongoing COVID pandemic highlights the importance of monitoring individuals' blood oxygenation (SpO2) before, during, and after exposure or infection.
  • The CIRCUL Ring should not be used as the sole determinant in any therapy, diagnosis, or treatment of patients.